Merck & Co

News

BMS scores an early victory in the new cancer biomarker batt...

Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo

News

NICE okays CDF funding for BMS' Opdivo in head and neck canc...

Cancer Drugs Fund will reimburse Opdivo for 2 years

News

Human Internal Organic - Human Heart, medical concept.

Merck axes cholesterol drug despite phase 3 success

Merck & Co has said it will not file anacetrapib with regulators

News

Merck axes hepatitis C drug development

Focus shifts to Keytruda amid competition from Gilead and shrinking market.

News

Novo showcases next-gen GLP-1 at EASD

Semaglutide is under review in Europe and US.

News

ESMO 2017 round up: BMS and AZ bounce back

Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.

BMS scores an early victory in the new cancer biomarker batt...

NICE okays CDF funding for BMS' Opdivo in head and neck canc...

Merck axes cholesterol drug despite phase 3 success

Merck axes hepatitis C drug development

Novo showcases next-gen GLP-1 at EASD

ESMO 2017 round up: BMS and AZ bounce back

Lilly points to long-lasting weight loss with orforglipron

How to meet your physicians where they are online

Merck &amp; Co

Editor's Picks

Merck & Co